pembrolizumabRecent, repeatedEvidence- NCT07815665 · Summit Therapeutics · Phase 3 · live · comparator · “Pembrolizumab” · registered Aug 2026
- NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Pembrolizumab” · registered Jun 2026
- NCT07287995 · Astellas Pharma Inc · Phase 2 · live · background · “Pembrolizumab” · registered Dec 2025
- NCT07218380 · Eli Lilly and Company · Phase 3 · live · background · “Pembrolizumab” · registered Oct 2025
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 99 studies | 99 studies | background 14 · comparator 2 |
CisplatinRecent, repeatedEvidence- NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Cisplatin” · registered Apr 2026
- NCT07393542 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine and cisplatin / carboplatin” · registered Jan 2026
- NCT07129993 · Daiichi Sankyo · Phase 3 · live · background · “Cisplatin” · registered Aug 2025
- NCT06592326 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3 · live · comparator · “Cisplatin/Carboplatin” · registered Sep 2024
- NCT06493552 · Vasgene Therapeutics, Inc · Phase 3 · live · comparator · “Cisplatin” · registered Jun 2024
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 77 studies | 1010 studies | background 8 · comparator 6 |
GemcitabineRecent, repeatedEvidence- NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2026
- NCT07393542 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine and cisplatin / carboplatin” · registered Jan 2026
- NCT07129993 · Daiichi Sankyo · Phase 3 · live · comparator · “Gemcitabine” · registered Aug 2025
- NCT06592326 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine” · registered Sep 2024
- NCT06493552 · Vasgene Therapeutics, Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Jun 2024
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 77 studies | 99 studies | background 7 · comparator 8 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07393542 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine and cisplatin / carboplatin” · registered Jan 2026
- NCT07287995 · Astellas Pharma Inc · Phase 2 · live · background · “Carboplatin” · registered Dec 2025
- NCT07129993 · Daiichi Sankyo · Phase 3 · live · background · “Carboplatin” · registered Aug 2025
- NCT06592326 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3 · live · comparator · “Cisplatin/Carboplatin” · registered Sep 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
| Eli Lilly and Company16% of its industry studies | 77 studies | 99 studies | background 8 · comparator 5 |
enfortumab vedotinRecent, repeatedEvidence- NCT07815665 · Summit Therapeutics · Phase 3 · live · background · “enfortumab vedotin (EV)” · registered Aug 2026
- NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Enfortumab vedotin” · registered Jun 2026
- NCT06493552 · Vasgene Therapeutics, Inc · Phase 3 · live · comparator · “Enfortumab vedotin” · registered Jun 2024
- NCT05845814 · Merck & Co., Inc · Phase 2 · live · background · “EV” · registered Apr 2023
- NCT03606174 · Bristol-Myers Squibb · Phase 2 · background · “Enfortumab vedotin” · registered Jul 2018
| Astellas Pharma Inc65% of its industry studiesUS: Astellas Pharma Inc (FDA 2019)EU: Astellas Pharma Inc (EMA 2022) | 44 studies | 44 studies | background 3 · comparator 2 |
NivolumabRecent, repeatedEvidence- NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Nivolumab” · registered Jun 2026
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
- NCT03633110 · Genocea Biosciences, Inc. · Phase 2 · background · “Nivolumab” · registered Aug 2018
- NCT03311334 · Sumitomo Pharma Co., Ltd. · Phase 2 · background · “Nivolumab” · registered Oct 2017
- NCT03241173 · Incyte Corporation · Phase 2 · background · “Nivolumab” · registered Aug 2017
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 22 studies | 33 studies | background 6 · comparator 1 |
toripalimabRecent, repeatedEvidence- NCT07314723 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 2 · live · background · “Toripalimab Injection” · registered Dec 2025
- NCT05302284 · RemeGen Co., Ltd. · Phase 3 · live · background · “Toripalimab” · registered Mar 2022
| RemeGen Co., Ltd.15% of its industry studiesUS: Coherus Biosciences, Inc. (FDA 2023)EU: Topalliance Biosciences Europe Limited (EMA 2024) | 22 studies | 22 studies | background 2 |